Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). Materials and Methods: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. Results: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/ pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). Conclusion: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.
Abstract
Background: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC). Materials and Methods: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation. Results: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/ pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases). Conclusion: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.
참고문헌 (41)
- Codjoe FS, "Carbapenem resistance: a review", Med Sci(Basel), 6, pp.1~ (2017)
- "The situation of antimicrobial resistance in health service areas from January to June 2019"[URL]
- Ting SW, "Risk factors and outcomes for the acquisition of carbapenem-resistant Gramnegative bacillus bacteremia : A retrospective propensity-matched case control study", J Microbiol Immunol Infect, 51, pp.621~628 (2018)
- Tamma PD, "Phenotypic detection of carbapenemase-producing organisms from clinical isolates", J Clin Microbiol, 56, pp.e01140~e01218 (2018)
- Sheu CC, "Infections caused by carbapenem-resistant Enterobacteriaceae : An update on therapeutic options", Front Microbiol, 10, pp.1~13 (2019)
- Santimaleeworagun W, "The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia", J Appl Pharm Sci, 10, pp.56~59 (2020)
- Prawang A, "Treatment and clinical outcome of Colistin-resistant Klebsiella pneumoniae bacteremia patients", Southeast Asian J Trop Med Public Health, 51, pp.263~269 (2020)
- Falagas ME, "Fosfomycin", Clin Microbiol Rev, 29, pp.321~347 (2016)
- Joukhadar C, "Target site penetration of fosfomycin in critically ill patients", J Antimicrob Chemother, 51, pp.1247~1252 (2003)
- Prawang A, "In vitro antibiotic synergy colistin-resistant Klebsiella pneumoniae", Southeast Asian J Trop Med Public Health, 50, pp.703~707 (2019)
- Albiero J, "Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae", Antimicrob Agents Chemother, 60, pp.4128~4139 (2016)
- Tseng SP, "The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan", J Microbiol Immunol Infect, 50, pp.653~661 (2017)
- VanScoy BD, "Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in Vitro infection model", Antimicrob Agents Chemother, 59, pp.7170~7177 (2015)
- "Clinical breakpoints -breakpoints and guidance"[URL]
- Lepak AJ, "In vivo pharmacokinetics and pharmacodynamics of ZTI-01(Fosfomycin for injection)in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa", Antimicrob Agents Chemother, 61, pp.1~11 (2017)
- Wang J, "Synergistic activity of colistin", fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an in vitro pharmacokinetic, BioMed Res Int, pp.2018, 2018[DOI]
- Fransen F, "Pharmacodynamics of fosfomycin against ESBL-and", or carbapenemase-producing Enterobacteriaceae, 2017, pp.72, 3374~3381
- Rodríguez-Gascón A, "Deciphering pharmacokinetics and pharmacodynamics of fosfomycin", Rev Esp Quimioter, 32(Suppl 1), pp.19~24 (2019)
- Santimaleeworagun W, "Optimization of fosfomycin doses for treating Pseudomonas aeruginosa infection in critically ill patients by using Monte Carlo simulation", TJPP, 11, pp.870~878 (2019)
- Asuphon O, "Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic", pharmacodynamic(PK, Int J Infect Dis, pp.2016, 50[DOI]
- Bradley JS, "Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation", Pediatr Infect Dis J, 22, pp.982~985 (2003)
- Khwaja A, "KDIGO clinical practice guidelines for acute kidney injury", Nephron Clin Pract, 120, pp.179~184 (2012)
- De Rosa FG, "Critical issues for Klebsiella pneumoniae KPCcarbapenemase producing K. pneumoniae infections : a critical agenda", Future Microbiol, 10, pp.283~294 (2015)
- Rhodes A, "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016", Intensive Care Med, 43, pp.304~377 (2017)
- Docobo-Pérez F, "Pharmacodynamics of fosfomycin : insights into clinical use for antimicrobial resistance", Antimicrob Agents Chemother, 59, pp.5602~5610 (2015)
- Shorr AF, "Intravenous fosfomycin for the treatment of hospitalized patients with serious infections", Expert Rev Anti Infect Ther, 15, pp.935~945 (2017)
- Michalopoulos AS, "The revival of fosfomycin", Int J Infect Dis, 15, pp.e732~e739 (2011)
- Bakthavatchalam YD, "Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence", Futur Sci OA, 6, pp.FSO461~ (2020)
- López-Montesinos I, "Oral and intravenous fosfomycin in complicated urinary tract infections", Rev Esp Quimioter, 32(Suppl 1), pp.37~44 (2019)
- Kaye KS, "Fosfomycin for injection(ZTI-01)versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis : ZEUS, a phase 2", 3 randomized trial, 2019, pp.69, 2045~2056
- Yaita K, "Biofilm-forming by carbapenem resistant enterobacteriaceae may contribute to the blood stream infection", Int J Mol Sci, 20, pp.5954~ (2019)
- Florent A, "Adverse events associated with intravenous fosfomycin", Int J Antimicrob Agents, 37, pp.82~83 (2011)
- Al-aloul M, "The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis", Clin Kidney J, 12, pp.652~658 (2019)
- Ordooei Javan A, "A review on colistin nephrotoxicity", Eur J Clin Pharmacol, 71, pp.801~810 (2015)
- Matzi V, "Extracellular concentrations of fosfomycin in lung tissue of septic patients", J Antimicrob Chemother, 65, pp.995~998 (2010)
- Roussos N, "Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections", Int J Antimicrob Agents, 34, pp.506~515 (2009)
- Scaglione F, "Pharmacokinetics", pharmacodynamics of antibacterials in the Intensive Care Unit : setting appropriate dosing regimens, 2008, pp.32, 294~301
- Roberts JA, "Monte Carlo simulations : maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients", J Antimicrob Chemother, 66, pp.227~231 (2011)
- Mahmoud SH, "Augmented renal clearance in critical illness : An important consideration in drug dosing", Pharmaceutics, 9, pp.1~27 (2017)
- Bilbao-Meseguer I, "Augmented renal clearance in critically ill patients : a systematic review", Clin Pharmacokinet, 57, pp.1107~1121 (2018)
- Silver LL, "Fosfomycin : Mechanism and resistance", Cold Spring Harb Perspect Med, 7, pp.1~11 (2017)